The discovery of antimicrobial drugs in the mid-twentieth century revolutionized medicine across the globe. Penicillin had already proven mold could combat bacterial infections, but it had a big problem: it couldn’t touch Gram-negative bacteria, which included Mycobacterium tuberculosis, the lethal bug that caused tuberculosis.
Rutgers University soil microbiologist Selman Waksman is credited for opening a new frontier in drug discovery. Waksman systematically screened soil organisms, established systematic protocols for drug discovery, and even coined the word antibiotic. In his laboratory he produced streptomycin, the world’s first effective treatment for tuberculosis.
But behind the public celebration, the Nobel Prize honors and corporate accolades was a dark, bitter legal battle. The man who actually isolated streptomycin and showed how useful it was against tuberculosis was a brilliant twenty-three-year-old graduate student working in a basement laboratory in Philadelphia. His name was Albert Schatz. When Waksman excluded Schatz from financial royalties and public credit, it ignited one of the most controversial legal lawsuits in modern science history.
In this deep dive, we’ll explore the life of Selman Waksman, the painstaking screening process that revolutionized drug discovery and the bitter legal battle over who rightfully deserved the credit for conquering tuberculosis.
The Soil Microbiologist and the Systematic Screening Approach
Born in 1888 in a small town in what is now the Ukraine, Selman Abraham Waksman He immigrated to the United States in 1910, where he studied soil chemistry and microbiology at Rutgers University and later received his doctorate from the University of California, Berkeley.
Back at Rutgers, Waksman became a faculty member and spent decades studying microbes in the soil, especially actinomycetes, a weird group of thread-like soil bacteria that share characteristics with fungi.
From Accidental Discovery to Careful Selection
Alexander Fleming famously discovered penicillin by accident when a stray mold spore contaminated a petri dish, but Waksman believed that drug discovery should not be left to chance. He developed a systematic screening methodology that changed pharmaceutical research:
- Isolation: Gathering hundreds of soil samples from farms, compost heaps and animal throats.
- Plating: Growing actinobacteria colonies along with pathogenic bacteria on agar plates.
- Observation: Clear zones could be seen around the colonies of actinomycetes where the pathogenic bacteria did not grow.
- Extraction and Testing: Finding the active chemical compounds and testing how toxic they are to living cells.
In 1941 Waksman coined the word antibiotic to describe chemical substances produced by microorganisms that inhibit or destroy the growth of other living microbes.
Waksman’s screening program yielded early compounds, such as actinomycin (1940) and streptothricin (1942). While these initial discoveries were good at killing bacteria, they were far too toxic for use in humans. The search went on for a safe, non-poisonous antibiotic.
The Discovery of Streptomycin and the Basement Lab
In 1943, Albert Schatz, a young graduate student who had been a medical laboratory technician in the U.S. Army, returned to Rutgers to work toward his Ph.D. under Waksman.
Because working with virulent tuberculosis bacteria posed extreme safety hazards, Waksman assigned Schatz to work in an isolated basement laboratory under the agriculture building. Schatz spent hours by himself plating soil cultures, watching for bacterial growth, and working with live Mycobacterium tuberculosis specimens.
Revelation
Schatz isolated two different strains of an actinomycete called Streptomyces griseus, on October 19, 1943, one from a heavily manured farm soil sample and the other from a swab from the throat of a healthy chicken.
The organism produced the chemical compound, which Schatz named streptomycin, that killed Gram-negative bacteria with remarkable potency. Most important, tests showed that streptomycin could stop the growth of tuberculosis bacteria completely and without the severe toxicity of earlier compounds.
Waksman told Schatz immediately. The two men collaborated on the landmark scientific paper announcing streptomycin, published in January 1944. Later that year, working with physicians William Feldman and Corwin Hinshaw at the Mayo Clinic, streptomycin was administered to human tuberculosis patients with miraculous results. Bedridden patients coughing blood recovered full health.
The Royal Controversy & The Secret Deal
The Rutgers Research and Endowment Foundation saw great commercial opportunity in streptomycin and allied with the drug giant Merck to produce the drug on a large scale.
At first, Waksman convinced Schatz to give up his patent rights to the university foundation for the symbolic amount of one dollar, on the grounds that as altruistic scientists working for the public good, neither of them should personally profit from a life-saving drug. Schatz willingly signed the document, thinking his mentor was taking the moral high ground.
Exposed the Betrayal
In 1949 Schatz made a disturbing discovery through newspaper accounts and university records. Schatz had not been paid, but Waksman had quietly arranged a private contract with the Rutgers Foundation:
- Waksman’s Cut: Waksman was receiving 10% of all worldwide royalties from streptomycin sales, which totaled hundreds of thousands of dollars per year (millions in today’s dollars).
- Foundation Share: The foundation took 80% of the royalties, and used the money to build a brand-new Institute of Microbiology, of which Waksman was the founding director.
- Share of Schatz: Albert Schatz got no royalties, no financial recognition.
And Waksman started saying in speeches, interviews and academic lectures that he alone had discovered streptomycin, and that Schatz was just a laboratory assistant who followed instructions.
The Suit Student Versus Mentor
Following the financial chicanery and the obliteration of his scientific identity, Albert Schatz took the extraordinary step of hiring a lawyer and suing Selman Waksman and the Rutgers Research Foundation for fraud and breach of trust in 1950.
In the 1950s, it was almost unthinkable to sue a senior professor as a graduate student in academia. Senior faculty members nationwide rallied behind Waksman, charging Schatz with greed, disloyalty and ingratitude. In effect, Schatz was ostracized by the scientific community.
The Settlement & Legal Recognition
When the case went to trial, Schatz’s legal team put forth a mountain of evidence, consisting of lab notebooks, dated experimental logs, and early correspondence showing that Schatz had independently isolated the specific strain, performed the critical assays, and demonstrated its effect against tuberculosis.
In December 1950, faced with public humiliation and possible legal defeat, Waksman and Rutgers settled the suit out of court.
The legal settlement established clear, legally binding stipulations:
- Legal Contract of Official Recognition as Co-Discoverer: The legal contract specifically named Albert Schatz as the official co-discoverer of streptomycin.
- Financial Redistribution: The settlement gave Schatz 3% of all future streptomycin royalties, while Waksman’s share was cut to 10%, and small percentages went to other laboratory workers who had helped in early testing.
- Formal Letter of Credit Waksman made a public statement that Schatz’s individual labor and scientific skill were essential to the discovery.
Intellectual Isolation The Nobel Prize Overlooked
Schatz won the court case and his share of royalties, but the academic fallout was devastating.
1952 Nobel Prize in Physiology or Medicine Nobel Committee for the discovery of streptomycin They gave the prize to Selman Waksman alone “for his ingenious, systematic and successful studies of the soil microbes that have led to the discovery of streptomycin.”
Albert Schatz was totally ignored by the Nobel Assembly.
A number of leading scientists rallied to Schatz’s protest, writing directly to the Nobel Committee to argue that awarding Waksman alone was a historical injustice. The committee did not change its decision, stating that Waksman was the director of the laboratory and had set up the overall program of screening.
A Career in the Shadow of War
Waksman received international recognition, international awards and the presidency of major scientific organizations, while Schatz spent decades trying to get prestigious academic appointments. Many university departments considered him a troublemaker who had sued his own professor.
For much of Schatz’s later career he was quietly employed as a professor of science education and soil chemistry at smaller institutions, continuing his research well outside the mainstream pharmaceutical spotlight.
Comparison of roles: Waksman and Schatz
The discovery of streptomycin requires us to disentangle the leadership of a research system from the hands-on laboratory breakthrough:
| Aspect | Selman Waksman | Albert Schatz |
|---|---|---|
| Primary Role | Director, strategist, and funding architect | Primary investigator and laboratory experimenter |
| Key Contribution | Created the systematic screening methodology for soil actinomycetes; coined “antibiotic.” | Isolated Streptomyces griseus, extracted streptomycin, and proved efficacy against tuberculosis. |
| Initial Recognition | Sole public credit, major media praise, 10% royalty contract. | Unpaid graduate student, excluded from original commercial royalties. |
| Legal Outcome | Royalties reduced; forced to sign legal agreement recognizing Schatz as co-discoverer. | Awarded 3% royalties and formal legal status as co-discoverer after the 1950 lawsuit. |
| Nobel Prize (1952) | Awarded the Nobel Prize in Physiology or Medicine. | Completely excluded by the Nobel Committee. |
Key Takeaways: Lessons from the Streptomycin Feud
The battle over streptomycin remains a classic case study in research ethics, patent law, and intellectual property rights within academia:
- Systematic Screening vs. Direct Discovery: Waksman built the industrial framework that made drug discovery repeatable, but Schatz performed the specific intellectual and physical labor that produced the breakthrough drug.
- The Importance of Laboratory Records: Schatz’s meticulous laboratory notebooks were the decisive evidence that saved his legal case, proving that physical documentation is a researcher’s greatest protection.
- Intellectual Property Rights for Students: The 1950 lawsuit established a vital precedent ensuring that graduate students and junior researchers are recognized and compensated when their laboratory work yields commercial patents.
- Ethics in Scientific Mentorship: The feud highlighted the ethical obligation of senior scientists to accurately attribute credit to junior colleagues rather than subsuming their work under administrative authority.
Final Thoughts: A Complex Legacy
Selman Waksman passed away in 1973, leaving behind an incredible scientific legacy. His systematic screening methods laid the groundwork for modern pharmaceutical research, leading directly to the discovery of dozens of life-saving antibiotics that transformed global health.
Albert Schatz passed away in 2005. In his later years, he finally received long-overdue recognition from various scientific bodies. In 1994, on the 50th anniversary of streptomycin’s discovery, Rutgers University awarded Schatz its highest honor, the Rutgers Medal, officially cementing his place alongside Waksman as co-discoverer of the drug that conquered tuberculosis.
The story of Waksman and Schatz reminds us that scientific breakthroughs are rarely simple, isolated events. They are complex human endeavors where vision, systematic planning, hands-on labor, and ethics collide—and where justice sometimes requires speaking truth to power.
